Furthermore, elevated bFGF plasma levels in brain tumor patients were correlated with a high mortality rate and poor survival, thus advancing the development of pharmacological inhibitors capable of directly interfering with the bFGF/FGFR signaling axis as a valid approach for brain tumor therapy [76]; however, further in-depth clinical studies are needed to clarify both the prognostic and the therapeutic value of bFGF in brain tumors. Here, FGF2 is linked to brain neoplasm.